The Effect of Short-term Bed Rest on Cardiac Function Measured by Cardiac Magnetic Resonance Imaging

The study will be conducted as a single-arm repeated measurement study in healthy participants (n=19). The participants will undergo a three and half-hour experimental day.

Initially, potential participants are invited to an information meeting and after informed consent, a control screening of MR contraindications is fulfilled. Following inclusion, the test day are conducted. The participants will arrive after a 4-hour period with no intake of food and drinks, except 250g of water, and by passive transportation (train, bus, or car). After arrival, a vein catheter is inserted into the antecubital vein. Then, a basal venous blood sample (-15 min) is drawn (4 ml in total) for analysis of plasma catecholamine and acetylcholine, and blood pressure is taken. Thereafter, the first basal CMRs will be performed with ECG monitoring.

During the test day, the participants will undergo five 15 min CMR imaging scans at 0, 30, 60, 120 and 180 mins. The first three are consecutive measurements with short breaks between, therefor the participants will lay in the scanner for the first 75 min and stay in bed in between the two sequential measurements. The participants will be in bedrest throughout the experimental day. Venous blood samples (4 ml) are obtained at 75, 110, and 170 min, where also blood pressure is taken. In total, up to 25 ml blood is obtained during the test day. The duration of the test day is 4.5 hour.

The time requirements for each participant are summarized:

• Information meeting and screening, approximately 1.5 hour
• 1 test day of approximately 4.5 hour.

Screening At the screening, height, and body weight will be measured, and a questionnaire on contraindications for CMR will be completed to ensure compliance to the scanner. The daily study leader will ask about previous illnesses, medication intake, alcohol, and smoking habits.

Statistical considerations Measures of myocardial function are highly reproducible when assessed using CMR, and interstudy and cohort coefficients of variation are in the range of 3%-5%10-12. In this study, the primary outcome is change in cardiac output after bed rest compared with the first CMR scanning before bed rest.

In an ongoing study, preliminary observations reveal a decrease of mean±SD -10±9% in CO and -4.1±5.9% in LVEF in both healthy participants and those with heart failure after two hours of bed rest, as evaluated by CMR.

For the upcoming study, the aim is to be able to detect a minimal effect difference of 10% and variation in the CMR data sampling as evident from unpublished observations described above. Sample size calculations were performed, considering a conservative approach with a power of 95% and a significance level of 0.05, utilizing paired Student's t-test for data evaluation. The calculations are as follows:

• For changes in CO, 11 participants would be sufficient to detect a 10% change.
• For changes in LVEF, 19 participants would be adequate to detect a 4% change. To account for potential dropouts or failed scans, the plan is to include, up to 29 participants, until 19 completed experimental days have been obtained .

In regard to the analysis plan, a t-test comparing the first (no bedrest) and the last CMR scan (4h bed rest) is the primary endpoint, further a mixed model will be performed to assess the difference in cardiac function throughout the day.

Participants Participants in this study consist of 19 healthy male and female participants.

Inclusion criteria

Male or female.

• Age between 18-80 years old.
• No use of medications with influence on heart function.
• For ethical reasons, we only include participants who are willing to be informed on new health information, as CMR may reveal relevant secondary health findings.

Exclusion criteria

• Diabetes, kidney, or liver disease.
• Contraindications to CMR, e.g., abdominal height exceed limitations of the MR-scanner, pacemaker, aortastent, neurostimulator, or other electronic device implanted, implanted metal devices, severe claustrophobia, or physiological diseases.
• Pregnant, lactating, or planning to become pregnant within the study period.
• In ongoing cancer treatment.
• Blood donation during and < 1 month prior to study.
• Simultaneous participation in other clinical trials potentially affecting the study outcome.
• Inability, physically or mentally, to comply with the procedure required by the study protocol ad evaluated by the primary investigator, study manager or clinical responsible.